Equities analysts expect Loxo Oncology Inc (NASDAQ:LOXO) to report ($0.77) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Loxo Oncology’s earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.74). Loxo Oncology reported earnings of ($0.69) per share during the same quarter last year, which would indicate a negative year over year growth rate of 11.6%. The business is expected to issue its next earnings report on Thursday, March 7th.

On average, analysts expect that Loxo Oncology will report full year earnings of ($3.48) per share for the current fiscal year, with EPS estimates ranging from ($5.86) to ($1.10). For the next year, analysts expect that the firm will post earnings of ($0.73) per share, with EPS estimates ranging from ($6.14) to $4.69. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Loxo Oncology.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.24). Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. The firm had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $38.55 million. During the same period in the previous year, the company earned ($2.45) earnings per share.

Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 29th. Zacks Investment Research lowered shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Piper Jaffray Companies set a $200.00 target price on shares of Loxo Oncology and gave the stock a “buy” rating in a research note on Wednesday, September 26th. JMP Securities lowered their target price on shares of Loxo Oncology from $221.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. Finally, Goldman Sachs Group assumed coverage on shares of Loxo Oncology in a research note on Monday, September 17th. They set a “neutral” rating and a $165.00 target price on the stock. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $190.31.

Shares of LOXO stock traded down $3.23 during mid-day trading on Friday, hitting $153.30. 46,063 shares of the stock were exchanged, compared to its average volume of 357,671. Loxo Oncology has a 52-week low of $71.45 and a 52-week high of $208.95. The firm has a market cap of $4.79 billion, a P/E ratio of -28.87 and a beta of 2.26.

In related news, VP Jennifer Burstein sold 2,500 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $166.96, for a total value of $417,400.00. Following the transaction, the vice president now directly owns 1,250 shares of the company’s stock, valued at approximately $208,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joshua H. Bilenker sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $166.20, for a total transaction of $3,324,000.00. The disclosure for this sale can be found here. Insiders sold a total of 70,000 shares of company stock worth $11,618,850 over the last ninety days. 17.10% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of LOXO. First Mercantile Trust Co. purchased a new position in Loxo Oncology in the 2nd quarter valued at about $122,000. Douglass Winthrop Advisors LLC acquired a new stake in Loxo Oncology in the 2nd quarter valued at about $204,000. Zeke Capital Advisors LLC acquired a new stake in Loxo Oncology in the 2nd quarter valued at about $208,000. Commonwealth Equity Services LLC acquired a new stake in Loxo Oncology in the 2nd quarter valued at about $209,000. Finally, Meeder Asset Management Inc. acquired a new stake in Loxo Oncology in the 2nd quarter valued at about $211,000. 95.58% of the stock is currently owned by hedge funds and other institutional investors.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

See Also: How to calculate compound interest

Get a free copy of the Zacks research report on Loxo Oncology (LOXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.